STOCK TITAN
  1. Home
  2. Sec-filings
  3. IDXX
  4. [Form 4] IDEXX LABORATORIES INC /DE Insider Trading Activity

[Form 4] IDEXX LABORATORIES INC /DE Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Michael Perkins Johnson reported equity award activity and related share settlements. He received stock options for 3,207 shares (non-qualified) and 162 shares (incentive) on February 12, 2026, along with 770 restricted stock units (RSUs), all at a grant price of $0.00 per share.

On February 14, 2026, 176, 179 and 218 RSUs were exercised into the same number of common shares at $0.00 per share. In a separate tax-withholding disposition, 178 common shares were delivered at $629.35 per share to cover tax obligations, leaving him with 2,794.687 directly owned common shares.

Positive

  • None.

Negative

  • None.
Insider Johnson Michael Perkins
Role Executive Vice President
Type Security Shares Price Value
Exercise Restricted Stock Unit 176 $0.00 $0.00
Exercise Restricted Stock Unit 179 $0.00 $0.00
Exercise Restricted Stock Unit 218 $0.00 $0.00
Exercise Common Stock 176 $0.00 $0.00
Exercise Common Stock 179 $0.00 $0.00
Exercise Common Stock 218 $0.00 $0.00
Exercise Price or Tax Liability Common Stock 178 $629.35 $112K
Grant/Award Non-Qualified Stock Option (right-to-buy) 3,207 $0.00 $0.00
Grant/Award Incentive Stock Option (right-to-buy) 162 $0.00 $0.00
Grant/Award Restricted Stock Unit 770 $0.00 $0.00
Holdings After Transaction: Non-Qualified Stock Option (right-to-buy) — 3,207 shares (Direct); Incentive Stock Option (right-to-buy) — 162 shares (Direct); Restricted Stock Unit — 1,954 shares (Direct); Common Stock — 2,794.687 shares (Direct)
Footnotes (8)
  1. F1. Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares.
  2. F2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
  3. F3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
  4. F4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
  5. F5. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027.
  6. F6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
  7. F7. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
  8. F8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Johnson Michael Perkins
(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)
WESTBROOK ME 04092
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/14/2026 M 176 A $0 2,575.687(1) D
Common Stock 02/14/2026 M 179 A $0 2,754.687 D
Common Stock 02/14/2026 M 218 A $0 2,972.687 D
Common Stock 02/14/2026 F 178 D $629.35(2) 2,794.687 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $617.2 02/12/2026 A 3,207 (3) 02/11/2036 Common Stock 3,207 $0 3,207 D
Incentive Stock Option (right-to-buy) $617.2 02/12/2026 A 162 (4) 02/11/2036 Common Stock 162 $0 162 D
Restricted Stock Unit (5) 02/12/2026 A 770 (5) (5) Common Stock 770 $0 770 D
Restricted Stock Unit (6) 02/14/2026 M 176 (6) (6) Common Stock 176 $0 176 D
Restricted Stock Unit (7) 02/14/2026 M 179 (7) (7) Common Stock 179 $0 356 D
Restricted Stock Unit (8) 02/14/2026 M 218 (8) (8) Common Stock 218 $0 652 D
Explanation of Responses:
1. Includes a total of 34.345 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on June 30, 2025, September 30, 2025 and December 31, 2025. There are a total of 163.687 shares held in the ESPP which has been increased by 0.001 shares due to a rounding calculation of previously issued fractional shares.
2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
5. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2027.
6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
7. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Michael P. Johnson 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR